AstraZeneca Launches Phase 1b/2 Trial of Dual CAR-T Therapy AZD0120 for Refractory Systemic Lupus Erythematosus
核心洞察
AstraZeneca has initiated a Phase 1b/2 clinical trial evaluating AZD0120, a novel CD19 (搜索)/BCMA (搜索) dual CAR-T cell therapy, for adult patients with refractory systemic lupus erythematosus (搜索).
The single-arm, open-label, multi-center study will first assess safety and tolerability in Phase 1b before advancing to Phase 2 to evaluate efficacy at the selected dose.
This represents a pioneering approach to treating autoimmune disease using dual-target CAR-T technology, potentially offering new hope for patients with treatment-resistant lupus.
AstraZeneca has launched a groundbreaking clinical trial investigating AZD0120, a CD19 (搜索)/BCMA (搜索) dual CAR-T cell therapy, as a potential treatment for adults with refractory systemic lupus erythematosus (搜索) (SLE (搜索)). The Phase 1b/2 study marks a significant advancement in applying CAR-T cell technology to autoimmune diseases, expanding beyond its established use in oncology.
Study Design and Objectives
The trial follows a single-arm, open-label, multi-center design structured in two distinct phases. The Phase 1b portion will focus on assessing the safety and tolerability of AZD0120 in patients with refractory SLE (搜索) cohorts. Following completion of Phase 1b, the study will advance to Phase 2, where researchers will evaluate both safety, tolerability, and efficacy of the selected dose in patients with refractory SLE.
Novel Dual-Target Approach
AZD0120 represents an innovative therapeutic approach, targeting both CD19 (搜索) and BCMA (搜索) antigens simultaneously. This dual-targeting strategy distinguishes it from traditional single-target CAR-T therapies and may offer enhanced therapeutic potential for patients with treatment-resistant autoimmune conditions.
Patient Population
The study will enroll adult participants specifically diagnosed with refractory systemic lupus erythematosus (搜索). This patient population represents individuals whose condition has not responded adequately to conventional treatments, highlighting the significant unmet medical need that AZD0120 aims to address.
Clinical Significance
The application of CAR-T cell therapy to autoimmune diseases like SLE (搜索) represents a paradigm shift in treatment approaches. While CAR-T therapies have demonstrated remarkable success in certain blood cancers, their potential in autoimmune conditions remains largely unexplored, making this trial particularly significant for the field.